Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sailong Pharmaceutical Group (002898) Fair Value & Analysis

Healthcare · CN · Market cap 1.5B CNY

Price¥8.30
Fair Value¥9.72
Upside+17.1%
Quality94/100
Evidence: Low Range ¥7.29 – ¥12.15

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Sailong Pharmaceutical Group (002898) currently trades at ¥8.30, while our model-based Fair Value estimate is ¥9.72 — implying the stock looks roughly 17.1% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. Sailong Pharmaceutical Group Co.,Ltd. was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co.,Ltd. in September 2021. The company was founded in 2002 and is based in Zhuhai, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Sailong Pharmaceutical Group (002898) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥9.72 versus a price of ¥8.30 — about +17% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 002898?
Our 21-model fair value for Sailong Pharmaceutical Group is ¥9.72 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥8.30.
What is the quality score of 002898?
Sailong Pharmaceutical Group has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.